InvestorsHub Logo
Followers 58
Posts 10198
Boards Moderated 1
Alias Born 09/21/2016

Re: georgejjl post# 464070

Saturday, 07/13/2024 10:18:55 AM

Saturday, July 13, 2024 10:18:55 AM

Post# of 464751
By Far,(IMO) the most important message-thought-process direction claim...is on SLIDE #4..

We believe we are positioned to capitalize on a significant and growing market opportunity to treat CNS diseases



https://www.anavex.com/_files/ugd/79bcf7_34621a802cb94006ba8b91012327d541.pdf

IMO, this is the thought process which has been driving Dr. M. and his team

AVXL is breaking the current FDA-CNS-investment problem solving collaborative models as applied WW down well beyond the limitations of Amyloid-FDA root cause model . Thankfully, the EU Medical Authority process model allows for an alternate regulatory path which allows for the next (critically important) sequence of trials to be run. The alliance of U.S. regulatory and financial-BP-WS -NIH systems have (until now) blocked any real progress on BioMed CNS diseases root cause (RWD-RWE). IMO, Dr.M. cannot say that but (in reality) that is what is going on. These slides are about what is FINALLY happening, IMO.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News